Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients von Yasenchak, Christopher A., Bordoni, Rodolfo Eduardo, Patel-Donnelly, Dipti, Larson, Tim, Goldschmidt, Jerome H., Boccia, Ralph V., Cline, Vivian Jean M., Forero-Torres, Andres, Sims, Robert Brownell, Newhook, Trevor, Friedberg, Jonathan W.

Volltext

Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma von Friedberg, Jonathan W., Forero-Torres, Andres, Holkova, Beata, Goldschmidt, Jerome H., Boccia, Ralph V., Bordoni, Rodolfo, Cline, Vivian Jean M., Patel-Donnelly, Dipti, Flynn, Patrick J., Olsen, Gregg A., Chen, Robert W., Galderisi, Faith, Wang, Yinghui, Sharman, Jeff Porter, Yasenchak, Christopher A.

Volltext

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type... von Cohn, Allen Lee, Hecht, J. Randolph, Dakhil, Shaker, Saleh, Mansoor N., Piperdi, Bilal, Cline-Burkhardt, Vivian Jean M., Tian, Ying, Go, William Y.

Volltext

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type... von Hecht, J. Randolph, Cohn, Allen Lee, Dakhil, Shaker R., Saleh, Mansoor N., Piperdi, Bilal, Cline-Burkhardt, Vivian Jean M., Tian, Ying, Go, William Y.

Volltext

Expression of Epidermal Growth Factor Receptors in Human Breast Cancer: Mass Versus Ligand Binding Capacity von Miseljic, Slobodan, Yang, Ai-Ru, Cline, Vivian Jean M., Wittliff, James L.

Volltext